Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing.
Biomark Res. 2020 Oct 30;8(1):56. doi: 10.1186/s40364-020-00238-9.
Biomark Res. 2020.
PMID: 33292642
Free PMC article.